MedTrace Logo

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

NCT00200499 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 845

Last updated 2005-12-16

No results posted yet for this study

Summary

The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.

Conditions

Interventions

DRUG

Nebivolol

Sponsors & Collaborators

  • Mylan Bertek Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Betty S. Riggs, MD, MBA · Mylan Pharmaceuticals Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Completion
2003-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00200499 on ClinicalTrials.gov